Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology, and nutrition sectors. Headquartered in Basel, Switzerland, Lonza provides a wide range of services and products, from active pharmaceutical ingredients (APIs) and biopharmaceuticals to cell and gene therapies and specialty ingredients for consumer health and nutrition. As a contract development and manufacturing organization (CDMO), Lonza partners with companies of all sizes to bring innovative medicines and products to market, leveraging its expertise in complex manufacturing processes, regulatory affairs, and quality control. Their operations span across North America, Europe, and Asia, supporting customers globally.
Serves as the central hub for Lonza's global strategic decision-making, corporate governance, finance, investor relations, and key administrative functions.
The Basel headquarters is a modern facility reflecting Lonza's commitment to innovation and sustainability, strategically located within a prominent European life sciences cluster.
The work culture at Lonza's HQ emphasizes collaboration, scientific excellence, precision, and a strong focus on quality and ethical practices, attracting a diverse international workforce.
Basel's significance lies in its rich history in the chemical and pharmaceutical industries, providing access to a skilled talent pool, research institutions, and a robust infrastructure for global operations.
Lonza operates a global network of more than 30 sites across North America, Europe, and Asia. These facilities support a wide range of functions including research and development, small and large molecule drug substance manufacturing, cell and gene therapy development and manufacturing, drug product services, and the production of ingredients for the nutrition and hygiene markets. This extensive footprint allows Lonza to serve its global customer base effectively and reliably.
Münchensteinerstrasse 38
Basel
Basel-Stadt
Switzerland
Address: 101 International Drive, Portsmouth, NH 03801, USA
Serves as a key manufacturing and development hub for North American and global clients, offering end-to-end solutions from clinical to commercial supply.
Address: Rottenstrasse 6, 3930 Visp, Switzerland
A critical site for European and global supply chains, known for its complex chemistry capabilities and advanced biomanufacturing facilities.
Address: 22921 Clawiter Rd, Hayward, CA 94545, USA
Supports the rapidly growing gene therapy market, particularly for clients on the US West Coast and globally, providing critical manufacturing capacity for life-saving treatments.
Address: 3 Biopolis Drive, Synapse #04-11, Singapore 138623
Supports Lonza's growth in the APAC region, providing localized support and manufacturing for pharmaceutical and biotech partners.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Lonza Group' leadership includes:
Lonza Group has been backed by several prominent investors over the years, including:
Lonza has experienced significant leadership changes in the past year, including the appointment of a new CEO, Wolfgang Wienand, who will succeed Pierre-Alain Ruffieux. Albert M. Baehny stepped down as Chairman, with Jean-Marc Huët elected as his successor.
Discover the tools Lonza Group uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Lonza Group primarily uses the 'firstname.lastname@lonza.com' email format for its employees. This is a common structure for large multinational corporations.
firstname.lastname@lonza.com
Format
jane.doe@lonza.com
Example
90%
Success rate
Lonza News Center • May 7, 2024
Shareholders approved all proposals by the Board of Directors, including the election of Jean-Marc Huët as the new Chairman, succeeding Albert M. Baehny. The dividend proposal was also approved....more
Lonza News Center • April 23, 2024
Lonza reported a solid performance for the first quarter of 2024, aligning with its full-year outlook. The company highlighted sustained demand in Biologics and ongoing strategic initiatives....more
Lonza News Center • January 25, 2024
Lonza announced the appointment of Wolfgang Wienand as its new Chief Executive Officer, effective summer 2024. He joins Lonza from Siegfried Holding AG, where he served as CEO....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Lonza Group, are just a search away.